| ZG005 / Suzhou Zelgen |
NCT06558227: Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 90 | RoW | ZG005 for Injection, ZG005, Bevacizumab, Avastin, Sintilimab, 达攸同 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Hepatocellular Carcinoma | 09/26 | 10/26 | | |
CTR20220021: A Phase I/II clinical study of ZG005 in patients with advanced solid tumors |
|
|
| Ongoing | 1/2 | 30 | China | ZG005 - Suzhou Zelgen | Suzhou Zelgen Biopharmaceutical Co., Ltd | | | | | |
NCT06233292: A Study of ZG005 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 484 | RoW | ZG005 Powder for Injection, ZG005 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Solid Tumors | 01/26 | 01/26 | | |
NCT06241235: Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma |
|
|
| Recruiting | 1/2 | 48 | RoW | ZG005 Powder for Injection, ZG005, Paclitaxel, Bevacizumab, Cisplatin, Carboplatin | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Cervical Carcinoma | 05/26 | 05/26 | | |
NCT06239298: A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1/2 | 130 | RoW | ZG005 Powder for Injection, ZG005, Donafenib Tosilate Tablets, Donafenib | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Solid Tumor | 03/26 | 05/26 | | |
ZG005-004, NCT06372626: Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. |
|
|
| Recruiting | 1/2 | 93 | RoW | ZG005, Etoposide, Cisplatin, Placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Neuroendocrine Carcinoma | 07/26 | 08/26 | | |
